Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 2Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Exocrine Pancreatic Insufficiency 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pancrelipase × Gastrointestinal × Clear all
NCT05642962 2026-02-25

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02985801 2021-03-15

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Mayo Clinic

Phase 1/2 Terminated
16 enrolled 5 charts
Gastrointestinal

Exocrine Pancreatic Insufficiency, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡